The transaction brings Fullerton’s total holding (direct and indirect) to 836,000 shares.
The company has begun discussions with International key opinion leaders (KOL’s) for mucopolysaccharidoses (MPS) clinical trial design and site selection.
MPS is a progressive rare disease caused by the absence or malfunctioning of lysosomal enzymes and has a severe unmet need.
Paradigm is focused on repurposing the drug pentosan polysulfate sodium in its injectable form (iPPS), a US FDA approved drug that has a long track record of safely treating inflammation.
The company is confident that a single successful phase 2/3 clinical trial will enable iPPS to be registered as a treatment for certain MPS indications.